Investment analysts at J P Morgan Chase & Co initiated coverage on shares of Abbott Laboratories (NYSE:ABT) in a research report issued to clients and investors on Friday. The firm set a “neutral” rating on the healthcare product maker’s stock.

Several other research firms also recently commented on ABT. Jefferies Group LLC reaffirmed a “buy” rating and issued a $58.00 price target on shares of Abbott Laboratories in a research note on Thursday, August 3rd. BMO Capital Markets reissued a “hold” rating and set a $53.00 target price on shares of Abbott Laboratories in a research report on Friday, September 1st. Cowen and Company reissued a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a research report on Thursday, August 17th. Royal Bank Of Canada reissued a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a research report on Tuesday. Finally, TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $54.40.

Abbott Laboratories (NYSE ABT) opened at 54.92 on Friday. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $55.11. The company’s 50 day moving average is $51.55 and its 200 day moving average is $47.69. The stock has a market cap of $95.42 billion, a PE ratio of 76.92 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.60 by $0.02. The company had revenue of $6.64 billion for the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The firm’s revenue was up 24.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.55 EPS. On average, analysts anticipate that Abbott Laboratories will post $2.49 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/abbott-laboratories-abt-coverage-initiated-by-analysts-at-j-p-morgan-chase-co/1612084.html.

In related news, insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total value of $9,729,225.00. Following the completion of the sale, the insider now directly owns 221,488 shares in the company, valued at approximately $10,963,656. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel Gesua Sive Salvadori sold 62,460 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $52.95, for a total transaction of $3,307,257.00. Following the completion of the sale, the insider now owns 113,426 shares of the company’s stock, valued at $6,005,906.70. The disclosure for this sale can be found here. Insiders sold a total of 333,310 shares of company stock worth $16,857,255 over the last 90 days. Company insiders own 0.76% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. McQueen Ball & Associates Inc. boosted its stake in Abbott Laboratories by 2.8% in the 3rd quarter. McQueen Ball & Associates Inc. now owns 47,791 shares of the healthcare product maker’s stock worth $2,550,000 after purchasing an additional 1,311 shares in the last quarter. Curbstone Financial Management Corp boosted its stake in Abbott Laboratories by 95.2% in the 3rd quarter. Curbstone Financial Management Corp now owns 39,728 shares of the healthcare product maker’s stock worth $2,120,000 after purchasing an additional 19,371 shares in the last quarter. Park National Corp OH boosted its stake in Abbott Laboratories by 0.4% in the 3rd quarter. Park National Corp OH now owns 602,236 shares of the healthcare product maker’s stock worth $32,135,000 after purchasing an additional 2,236 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in Abbott Laboratories in the 2nd quarter worth approximately $1,038,000. Finally, Frontier Investment Mgmt Co. boosted its stake in Abbott Laboratories by 18.8% in the 2nd quarter. Frontier Investment Mgmt Co. now owns 10,095 shares of the healthcare product maker’s stock worth $491,000 after purchasing an additional 1,598 shares in the last quarter. Institutional investors own 71.50% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.